4d Molecular Therapeutics, INC. (FDMT) — 10-Q Filings

All 10-Q filings from 4d Molecular Therapeutics, INC.. Browse 5 Quarterly Report reports with AI-powered summaries and risk analysis.

10-Q Filings (5)

4D Molecular Therapeutics' Losses Widen Amid R&D Surge — Aug 11, 2025 Risk: high
4D Molecular Therapeutics, Inc. reported a net loss of $62.1 million for the three months ended June 30, 2025, an increase from a net loss of $50.3 million for
4D Molecular Therapeutics Files Q1 2025 10-Q — May 8, 2025 Risk: medium
4D Molecular Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial performance and business operations,
4D Molecular Therapeutics Q3 Update — Nov 13, 2024 Risk: medium
4D Molecular Therapeutics, Inc. reported its third-quarter results for the period ending September 30, 2024. The company's financial filings indicate activities
4D Molecular Therapeutics Q2 2024 Update — Aug 8, 2024 Risk: medium
4D Molecular Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial activities, including its public offer
4D Molecular Therapeutics Files 10-Q for Period Ending March 31, 2024 — May 9, 2024 Risk: medium
4D Molecular Therapeutics, Inc. (FDMT) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. 4D Molecular Therapeutics, Inc. filed a 10-Q report for the

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX